For patients’ sera and ovarian cancer tissue, it has been shown that a combination of CA-125 and Galectin-1 serves as a possible two-marker combination for preoperative discrimination of benign and malignant ovarian masses [13]. This evidence concerns the gene LGALS1 and ovarian carcinoma.